SeekPeptides has compiled this resource because the conversation around GLP-1 medications and female sexuality deserves more than vague reassurances
The mean follow-up on-treatment was 181 days (median 155 days, IQR 71 to 290 days) for tirzepatide initiators and 174 days (median 148 days, IQR 82 to 254 days) for semaglutide initiators
The post-menopausal state is marked by relative insulin resistance, increased systemic inflammation, and altered hunger signaling
Who qualifies, and what results look like, are individual, and we settle that at the consultation
As coverage policies evolve and formulations change, staying informed will help you make the most cost-effective decision for your care
What should I do if I miss a weekly dose during the dose schedule